Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis - PubMed (original) (raw)
Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis
Y Martinet et al. N Engl J Med. 1987.
Abstract
Idiopathic pulmonary fibrosis is a fibrotic lung disease characterized by an increased number of mesenchymal cells in the alveolar walls. Alveolar macrophages constitutively express low levels of c-sis, the protooncogene coding for the B chain of platelet-derived growth factor, a protein with chemotactic and mitogenic activity toward mesenchymal cells. We therefore hypothesized that alveolar macrophages in patients with idiopathic pulmonary fibrosis may release increased amounts of platelet-derived growth factor, which might help to explain the accumulation of mesenchymal cells and the fibrosis of the lower respiratory tract in the disease. Evaluation of alveolar macrophages recovered from the lungs of patients with idiopathic pulmonary fibrosis demonstrated that these cells spontaneously released four times more platelet-derived growth factor than did alveolar macrophages recovered from normal persons (P less than 0.01). That the platelet-derived growth factor molecules were potentially active was shown by their chemotactic activity for smooth-muscle cells and their ability to act as a "competence" factor for fibroblast growth. These observations suggest the possibility that the accumulation of mesenchymal cells within the alveolar walls in patients with idiopathic pulmonary fibrosis may result partly from the exaggerated release of the potent mitogen platelet-derived growth factor by mononuclear phagocytes in the lower respiratory tract.
Similar articles
- Mechanisms of pulmonary fibrosis. Spontaneous release of the alveolar macrophage-derived growth factor in the interstitial lung disorders.
Bitterman PB, Adelberg S, Crystal RG. Bitterman PB, et al. J Clin Invest. 1983 Nov;72(5):1801-13. doi: 10.1172/JCI111140. J Clin Invest. 1983. PMID: 6630527 Free PMC article. - Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis.
Nagaoka I, Trapnell BC, Crystal RG. Nagaoka I, et al. J Clin Invest. 1990 Jun;85(6):2023-7. doi: 10.1172/JCI114669. J Clin Invest. 1990. PMID: 2347924 Free PMC article. - [Pathogenesis of idiopathic interstitial pneumonia/idiopathic pulmonary fibrosis: cellular and molecular biology of the disease].
Yoshimura K. Yoshimura K. Nihon Kyobu Shikkan Gakkai Zasshi. 1993 Dec;31 Suppl:20-31. Nihon Kyobu Shikkan Gakkai Zasshi. 1993. PMID: 8007466 Review. Japanese. - Control of lung fibroblast proliferation by macrophage-derived platelet-derived growth factor.
Brody AR. Brody AR. Ann N Y Acad Sci. 1994 May 28;725:193-9. doi: 10.1111/j.1749-6632.1994.tb39801.x. Ann N Y Acad Sci. 1994. PMID: 8030989 Review. No abstract available.
Cited by
- Transformation of macrophages into myofibroblasts in fibrosis-related diseases: emerging biological concepts and potential mechanism.
Li X, Liu Y, Tang Y, Xia Z. Li X, et al. Front Immunol. 2024 Sep 25;15:1474688. doi: 10.3389/fimmu.2024.1474688. eCollection 2024. Front Immunol. 2024. PMID: 39386212 Free PMC article. Review. - Multiscale computational model predicts how environmental changes and drug treatments affect microvascular remodeling in fibrotic disease.
Leonard-Duke J, Agro SMJ, Csordas DJ, Bruce AC, Eggertsen TG, Tavakol TN, Barker TH, Bonham CA, Saucerman JJ, Taite LJ, Peirce SM. Leonard-Duke J, et al. bioRxiv [Preprint]. 2024 Mar 22:2024.03.15.585249. doi: 10.1101/2024.03.15.585249. bioRxiv. 2024. PMID: 38559112 Free PMC article. Preprint. - Crosstalk between fibroblasts and immunocytes in fibrosis: From molecular mechanisms to clinical trials.
Di X, Chen J, Li Y, Wang M, Wei J, Li T, Liao B, Luo D. Di X, et al. Clin Transl Med. 2024 Jan;14(1):e1545. doi: 10.1002/ctm2.1545. Clin Transl Med. 2024. PMID: 38264932 Free PMC article. Review. - Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis.
Perrot CY, Karampitsakos T, Herazo-Maya JD. Perrot CY, et al. Am J Physiol Cell Physiol. 2023 Oct 1;325(4):C1046-C1057. doi: 10.1152/ajpcell.00302.2023. Epub 2023 Sep 11. Am J Physiol Cell Physiol. 2023. PMID: 37694283 Free PMC article. Review. - Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis.
Aripova N, Duryee MJ, England BR, Hunter CD, Mordeson JE, Ryan EM, Daubach EC, Romberger DJ, Thiele GM, Mikuls TR. Aripova N, et al. Front Immunol. 2023 Aug 16;14:1203548. doi: 10.3389/fimmu.2023.1203548. eCollection 2023. Front Immunol. 2023. PMID: 37654483 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical